MAGEA3 and colorectal carcinoma: Given the urgent clinical need for reliable biomarkers to predict treatment response and improve bevacizumab efficacy, our findings suggest that MAGEA3 may serve as a valuable prognostic marker and a potential therapeutic target in CRC.